Processa Pharmaceuticals (PCSA) Net Margin (2012 - 2016)
Processa Pharmaceuticals' (PCSA) quarterly Net Margin came in at 2886.6% in Q1 2016, down 88662.0% YoY from N/an in Q2 2015, and down 35.22% on a QoQ basis from 2134.79% in Q4 2015.
Processa Pharmaceuticals (PCSA) Net Margin (2012 - 2016) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 5 years of Net Margin data on file, last reported at 2886.6% in Q1 2016.
- Quarterly Net Margin fell 88662.0% year-over-year to 2886.6% in Q1 2016, while the trailing twelve-month figure through Dec 2016 was 7580.82% (down 371571.0% YoY) and the FY2016 annual result came in at 7580.8%, down 458572.0% from the prior year.
- Net Margin eased to 2886.6% in Q1 2016, from 2134.79% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 561.41% in Q2 2012 to a low of 19875.88% in Q4 2014.
- A 5-year average of 4015.15% and a median of 1871.27% in 2015 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2014 — Net Margin tumbled 1919998 bps — and 2015, when it surged 1774108 bps.
- Tracing PCSA's Net Margin over 5 years: stood at 2808.09% in 2012, then surged by 76 bps to 675.9% in 2013, then sank by 2841 bps to 19875.88% in 2014, then jumped by 89 bps to 2134.79% in 2015, then plunged by 35 bps to 2886.6% in 2016.
- The last three Net Margin figures came in at 2886.6% (Q1 2016), 2134.79% (Q4 2015), and 1742.55% (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -2,886.60% |
| Dec 31, 2015 | -2,134.79% |
| Sep 30, 2015 | -1,742.55% |
| Jun 30, 2015 | -10,288.49% |
| Mar 31, 2015 | -1,999.98% |
| Dec 31, 2014 | -19,875.88% |
| Sep 30, 2014 | -1,656.83% |
| Jun 30, 2014 | -1,184.87% |
| Mar 31, 2014 | -10,719.57% |
| Dec 31, 2013 | -675.90% |
| Sep 30, 2013 | -740.69% |
| Jun 30, 2013 | -789.84% |
| Mar 31, 2013 | -4,767.22% |
| Dec 31, 2012 | -2,808.09% |
| Sep 30, 2012 | -1,409.73% |
| Jun 30, 2012 | -561.41% |